← Leaderboards
Winston Alexander Hide
Harvard School Of Public Health
$3,832,830
Attributed
$9,142,367
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,142,367 · 5
By mechanism
R01$6,495,503 · 3
RF1$2,173,794 · 1
S10$473,070 · 1
Top collaborators
- Doo Yeon Kim8 shared
- Reto Guler5 shared
- Rudolph Emile Tanzi5 shared
- Frank J. Slack3 shared
- Se Hoon Choi1 shared
Most similar at Harvard School Of Public Health
Same institution · by research overlap
- Christopher Michael Hine$3,497,811
- Kristopher Burkewitz$2,935,373
- Francesca Guglielmini Tomasi$21,609
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposGenesResiliencePathway InteractionsGene ExpressionPharmaceutical PreparationsGeneticCohortAffectPathogenicityTranscriptomeDrug TargetingImpaired CognitionDementiaHuman SubjectNeuropathologyNeuroprotectionBiologyCell ModelCognitiveMolecularAmyloid Beta-ProteinNeurofibrillary TanglesCognition
Grant awards (15)
Non-coding RNAs in resilience to Alzheimerâs Disease$827,394
R01 · FY2025 · AG
Targeting non-coding RNAs as host-directed drug therapy for tuberculosis$129,659
R01 · FY2025 · AI
Resilience to Alzheimer's disease by targeting adult hippocampal neurogenesis$2,173,794
RF1 · FY2024 · AG
Non-coding RNAs in resilience to Alzheimerâs Disease$844,278
R01 · FY2024 · AG
Targeting non-coding RNAs as host-directed drug therapy for tuberculosis$131,718
R01 · FY2024 · AI
Non-coding RNAs in resilience to Alzheimerâs Disease$862,503
R01 · FY2023 · AG
The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.$653,770
R01 · FY2023 · AG
Targeting non-coding RNAs as host-directed drug therapy for tuberculosis$131,642
R01 · FY2023 · AI
The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.$656,115
R01 · FY2022 · AG
Targeting non-coding RNAs as host-directed drug therapy for tuberculosis$132,596
R01 · FY2022 · AI
The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.$658,414
R01 · FY2021 · AG
Targeting non-coding RNAs as host-directed drug therapy for tuberculosis$120,556
R01 · FY2021 · AI
The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.$660,668
R01 · FY2020 · AG
The Alzheimer's Disease Resiliome: Pathway Analysis and Drug Discovery.$686,190
R01 · FY2019 · AG
Modern Public Health data storage for High Volume using the PowerVault MD3000$473,070
S10 · FY2011 · RR · contact PI